Lees-Rolfe Garth
SEC insider (Form 3/4/5 filer). CIK 0002017374. Director at LUDWIG ENTERPRISES, INC. (LUDG) and 1 other issuer. 7 reported Form 4/5 transactions since Sep 2024; latest on Jan 21, 2025. Located in LEXINGTON, MA.
Companies Lees-Rolfe Garth has filed insider reports for
- LUDWIG ENTERPRISES, INC. (LUDG): Director
- Inhibikase Therapeutics, Inc. (IKT): Officer, Chief Financial Officer
Lees-Rolfe Garth
CIK: 0002017374
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
5.8K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
5.8K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
DispositionDirectStock Option (Right to Buy)
90K shares- - Jan 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
90K shares- - Jan 3, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
470.9K shares- - Jan 3, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
235.4K shares- - Jan 3, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
432.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 21, 2025 |  IKT Inhibikase Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 5,834 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 5,834 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Disposition Stock Option (Right to Buy) | 90,000 | - | - | Direct |
| Jan 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 90,000 | - | - | Direct |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 470,861 | - | - | Direct |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 235,383 | - | - | Direct |
| Jan 3, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 432,853 | - | - | Direct |
1-7 of 7 transactions